Last reviewed · How we verify
Raltegravir Film-coated Tablet
At a glance
| Generic name | Raltegravir Film-coated Tablet |
|---|---|
| Also known as | ISENTRESS®, MK-0518 |
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety & Efficacy of Dual Therapy With Raltegravir/Lamivudine (PHASE3)
- Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents (PHASE1, PHASE2)
- A Drug Interaction Study to Assess the Pharmacokinetics of Narlaprevir and Antiretroviral Drugs (PHASE1)
- A Study of the Safety, Tolerability, and Antiretroviral Activity of Raltegravir (MK-0518) in Combination With Other Antiretroviral Therapies in Russian Children and Adolescents Infected With Human Immunodeficiency Virus (HIV-1) (MK-0518-248) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Raltegravir Film-coated Tablet CI brief — competitive landscape report
- Raltegravir Film-coated Tablet updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI